Search of anti-adriamycin antibodies in serum of cancer patients under chemotherapic treatment.
The exposure to DNA reactive carcinogens is known to elicit a specific humoral immunological response, with the production of antibodies towards the carcinogen adducts. In analogy to chemical carcinogens, any chemotherapic, like Adriamycin, undergoes the same adduct formation, and for this reason could elicit specific antibodies. In this case we can suppose that an eventual immunological response could influence the efficacy of chemotherapy. The aim of this study was to verify if adriamycin adducted to DNA or transport proteins can elicit an immunological response of specific anti-adriamycin (ADM) antibodies in sera of 43 cancer patients treated with the drug. No specific antibodies were detected in these individuals. The lack of anti-adriamycin antibodies suggests that the therapeutic exposure to the drug does not elicit a specific immunological response.
Verdina
A
A
Regina Elena Institute for Cancer Research, Rome, Italy.
Tonachella
R
R
Colella
E
E
Falasca
G
G
Galati
R
R
D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use; D018736:DNA Adducts / Q000276:immunology*; D004317:Doxorubicin / Q000276:immunology* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D015251:Epirubicin / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy
D000970:Antineoplastic Agents; D018736:DNA Adducts; D007074:Immunoglobulin G; D015251:Epirubicin; D004317:Doxorubicin